S
Steven D. Gore
Researcher at Yale University
Publications - 298
Citations - 10085
Steven D. Gore is an academic researcher from Yale University. The author has contributed to research in topics: Myelodysplastic syndromes & Azacitidine. The author has an hindex of 49, co-authored 298 publications receiving 9157 citations. Previous affiliations of Steven D. Gore include University of Maryland, Baltimore & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology
Margaret R. O'Donnell,Martin S. Tallman,Camille N. Abboud,Jessica K. Altman,Frederick R. Appelbaum,Daniel A. Arber,Vijaya Raj Bhatt,Dale L. Bixby,William Blum,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Steven D. Gore,Aric C. Hall,Patricia Kropf,Jeffrey E. Lancet,Lori J. Maness,Guido Marcucci,Michael Gary Martin,Joseph O. Moore,Rebecca L. Olin,Deniz Peker,Daniel A. Pollyea,Keith W. Pratz,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Eunice S. Wang,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger and older adult patients.
Journal ArticleDOI
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes
Peter L. Greenberg,Eyal C. Attar,John M. Bennett,Clara D. Bloomfield,De Castro Cm,Deeg Hj,James M. Foran,Karin M.L. Gaensler,G. Garcia-Manero,Steven D. Gore,David R. Head,Rami S. Komrokji,Lori J. Maness,Michael Millenson,Stephen D. Nimer,M R O'Donnell,Mark A. Schroeder,Paul J. Shami,Richard Stone,James E. Thompson,Peter Westervelt +20 more
TL;DR: Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.
Journal ArticleDOI
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet,Zhuoxin Sun,Maria E. Figueroa,Rhett P. Ketterling,Ari Melnick,Peter L. Greenberg,James G. Herman,Mark B. Juckett,Eunice S. Wang,Mitchell R. Smith,Lisa Malick,Elisabeth Paietta,Magdalena Czader,Mark R. Litzow,Janice Gabrilove,Harry P. Erba,Steven D. Gore,Martin S. Tallman +17 more
TL;DR: Addition of entinostat to AZA did not increase clinical response as defined by the protocol and was associated with pharmacodynamic antagonism, however, the prolonged administration of AZA by itself seems to increase HN rate compared with standard dosing and warrants additional investigation.
Journal ArticleDOI
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres,Mikkael A. Sekeres,Megan Othus,Alan F. List,Olatoyosi Odenike,Richard Stone,Steven D. Gore,Mark R. Litzow,Rena Buckstein,Min Fang,Diane Roulston,Clara D. Bloomfield,Anna Moseley,Aziz Nazha,Yanming Zhang,Mario R. Velasco,Rakesh Gaur,Ehab Atallah,Eyal C. Attar,Elina K. Cook,Alyssa Cull,Michael J. Rauh,Frederick R. Appelbaum,Harry P. Erba +23 more
TL;DR: Patients with higher-risk MDS treated with azacitidine-based combinations had similar ORR to azac itidine monotherapy, although patients with CMML benefitted from azacItidine plus lenalidomide.